~~<i id='917614A405'><strike id='917614A405'><tt id='917614A405'><pre id='917614A405'></pre></tt></strike></i>~~

Home» explore» focus

focus

author：Wikipedia 2025-09-30 23:31:16 Page View：82297

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Many immigrants are left out of maternal health programs
Next article： Continuity nursing helped my family in our darkest PICU moments

comprehensive

Activists slam private health insurers over coverage restrictions

ProtestorsoutsideAmerica'sHealthInsurancePlansheadquarters.CourtesyPeople'sActionWASHINGTON—Hun

STAT Readout Newsletter: Today in biotech, life science news

AdobeWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsletterinyo

Medical leaders decry Supreme Court decision on affirmative action

STEFANIREYNOLDS/AFPviaGettyImagesMedicalleadersonThursdayreactedswiftlytotheSupremeCourt’sdecisionto

Teacher posts viral 'school supply rant' with advice for parents

1:28TeacherKatieAlburgerholdsupafidgettoolwhileshoppingforback-to-schoolsupplies.@_adaywithmissa/Tik